EC Paediatrics

The principles of providing care to patients with acute pneumonia (AP) that have developed over many centuries were formed exclusively on the basis of empirical experience and were focused on achieving a quick and tangible effect, but, above all, on the basis of subjective assessments. The insufficient development of medical science and the lack of research resources did not allow doctors of that period to purposefully determine the therapeutic potential of the methods used, determine their expediency and place in the treatment of this category of patients.

1. Abraham EP and Chain E. “An enzyme from bacteria able to destroy penicillin. 1940”. Reviews of Infectious Diseases 4 (1988): 677-678.
2. Rammelkamp T. “Resistance of Staphylococcus aureus to the action of penicillin”. Experimental Biology and Medicine 3 (1942): 386-389.
3. Fleming A. "The Nobel Prize in Physiology or Medicine 1945 - Penicillin: Nobel Lecture". NobelPrize.org. (1945).
4. Aminov RI. "A brief history of the antibiotic era: lessons learned and challenges for the future". Frontiers in Microbiology 1 (2010): 134.
5. Gadsby NJ and Musher DM. “The microbial etiology of community-acquired pneumonia in adults: from classical bacteriology to host transcriptional signatures”. Clinical Microbiology Reviews 4 (2022): e00015-22.
6. C Heneghan., et al. “Differentiating viral from bacterial pneumonia”. The Centre for Evidence-Based Medicine. Evidence Service to support the COVID-19 response. University of Oxford (2020).
7. Kamat IS., et al. “Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis”. Clinical Infectious Diseases 3 (2020): 538-542.
8. Lhommet C., et al. “Predicting the microbial cause of community-acquired pneumonia: can physicians or a data-driven method differentiate viral from bacterial pneumonia at patient presentation?” BMC Pulmonary Medicine 1 (2020): 62.
9. Kyriazopoulou E., et al. “BioFire^® FilmArray^® pneumonia panel for severe lower respiratory tract infections: subgroup analysis of a randomized clinical trial”. Infectious Diseases and Therapy 3 (2021): 1437-1449.
10. Montes-Andujar L., et al. “Empiric antibiotics for community-acquired pneumonia in adult patients: a systematic review and a network meta-analysis”. Thorax 10 (2021): 1020-1031.
11. Cilloniz C., et al. “Management of pneumonia in critically ill patients”. British Medical Journal 375 (2021): e065871.
12. Enne VI., et al. “Multicentre evaluation of two multiplex PCR platforms for the rapid microbiological investigation of nosocomial pneumonia in UK ICUs: the INHALE WP1 study”. Thorax12 (2022): 1220-1228.
13. Alex R Schuurman., et al. “The host response in different aetiologies of community-acquired pneumonia”. EBioMedicine 81 (2022): 104082.
14. Jeremy Hsu. “AI discovers new class of antibiotics to kill resistant bacteria”. New Scientist3472 (2024).
15. I Klepikov. “Myths, legends and real facts about acute lung inflammation”. Cambridge Scholars Publishing (2024): 338.
16. Schwiegk H. “Der Lungenentlastungsreflex”. Pflüger's Archiv für die gesamte Physiologie des Menschen und der Tiere 236 (1935): 206-219.
17. Olivia Vynn. “Cardiology secrets”. Chapter 41, p. 210. Adair Edition: 2, illustrated Published by Elsevier Health Sciences (2001).
18. "Normal Hemodynamic Parameters - Adult". Edwards Lifesciences LLC (2010).
19. Richards G., et al. “CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS”. Journal of Intensive Care Medicine 1 (2011): 34-40.
20. Singer M., et al. “The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)”. Journal of the American Medical Association 8 (2016): 801-810.
21. Phua J., et al. “Characteristics and outcomes of culture-negative versus culture-positive severe sepsis”. Critical Care 5 (2013): R202.
22. Kaukonen KM., et al. “Systemic inflammatory response syndrome criteria in defining severe sepsis”. New England Journal of Medicine 17 (2015): 1629-1638.
23. Ceccato A and Torres A. “Sepsis and community-acquired pneumonia”. Annals of Research Hospitals 2 (2018): 7.
24. Cilloniz C., et al. “Pure viral sepsis secondary to community-acquired pneumonia in adults: risk and prognostic factors”. Journal of Infectious Diseases 7 (2019): 1166-1171.
25. Xiaoying Gu., et al. “Respiratory viral sepsis: epidemiology, pathophysiology, diagnosis and treatment”. European Respiratory Review157 (2020): 200038.
26. BD Huttner., et al. “COVID-19: don't neglect antimicrobial stewardship principles!” Clinical Microbiology and Infection7 (2020): 808-810.
27. B Beovic., et al. “Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey”. Journal of Antimicrobial Chemotherapy11 (2020): 3386-3390.
28. Rawson TM., et al. “Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing”. Clinical Infectious Diseases 9 (2020): 2459-2468.
29. LO Gostin and GK Gronvall. “The Origins of Covid-19 — Why It Matters (and Why It Doesn’t)”. New England Journal of Medicine 25 (2023): 2305-2308.
30. Antimicrobial resistance (2021).
31. Antimicrobial resistance (2023).
32. Bruce K Rubin and Jeffrey M Haynes. “Myths, misunderstandings, and dogma in respiratory care”. Respiratory Care8 (2012): 1314-1324.